Phase II Clinical Trial of Tasly Biopharma PUK (Recombinant Human Pro-urokinase for Injection) Thrombolysis for the Treatment of Acute Pulmonary Embolism Successfully Completes the Enrollment

Phase II Clinical Trial of Tasly Biopharma PUK (Recombinant Human Pro-urokinase for Injection) Thrombolysis for the Treatment of Acute Pulmonary Embolism Successfully Completes the Enrollment